PTC Therapeutics Inc. sell nvestor
Start price
16.09.23
/
50%
€24.00
Target price
16.09.24
€12.00
Performance (%)
-13.33%
End price
30.09.23
€20.80
Summary
This prediction ended on 30.09.23 with a price of €20.80. The price of PTC Therapeutics Inc. decreased from the start of the prediction. Compared to the start price this resulted in a performance of -13.33%. nvestor has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| PTC Therapeutics Inc. | 0.671% | 0.671% |
| iShares Core DAX® | 3.178% | 0.980% |
| iShares Nasdaq 100 | 2.972% | 0.925% |
| iShares Nikkei 225® | 0.545% | -4.556% |
| iShares S&P 500 | 2.367% | 0.833% |
According to nvestor what are the pros and cons of PTC Therapeutics Inc. for the foreseeable future?
Pros
Cons
Probably not worthwhile Investment
Revenue decline/stagnation expected
Lower EBIT Margin than peer group
negative Cash Flow expected
Bad rating
Little Investments for future growth
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Below average Management
Bad culture
Little innovation
Few uniques
Growths slower than the competition
high free float
Higher risks for its business
Significant cyclical dependencies
Little known brand
Business model of the past or high risk
High valuation
Low dividend yield expected
Dependend from some customers or products
Sustainability is little important
Below average Marketposition
EBIT decline/stagnation expected
Comments by nvestor for this prediction
In the thread PTC Therapeutics Inc. diskutieren
In the thread Trading PTC Therapeutics Inc.
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.
Stopped prediction by nvestor for PTC Therapeutics Inc.
PTC Therapeutics Inc.
Start price
Target price
Perf. (%)
€17.20
28.10.23
28.10.23
€8.00
28.10.24
28.10.24
-4.07%
11.11.23
11.11.23
Probably not worthwhile Investment
Revenue decline/stagnation expected
Lower EBIT Margin than peer group
negative Cash Flow expected
